Gain and loss of function experiments using the Aldh1l1‐Cre/ERT2 recombinase in models of neuroinflammatory, ischemic, and neurodegenerative diseases must account for potential mutational contributions in both astrocytes and peripheral immune cells to reported phenotypes. This evidence concerns the gene MAPK3 and neurodegenerative disease.